SynthesisScientific reports2026
Predictive value of FST for renal replacement therapy in patients with acute kidney injury: a meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The furosemide stress test (FST) has been used as a predictor for renal replacement therapy (RRT), yet its reported performance varies across studies. This meta-analysis aimed to evaluate the predictive value of FST for RRT in patients with acute kidney injury (AKI). We searched PubMed, Embase, Cochrane, CNKI, and Wanfang Medical databases up to December 13, 2025, for prospective or retrospective cohort studies reporting the predictive performance of FST for RRT. This trial has been registered in PROSPERO (CRD42024570956). A total of 14 studies with 3506 AKI patients were included. The pooled sensitivity and specificity of FST in predicting RRT were 0.76 (95% CI 0.67–0.83) and 0.77 (95% CI 0.69–0.84), respectively. The pooled positive likelihood ratio was 3.36 (95% CI 2.44–4.26), and the pooled negative likelihood ratio was 0.31 (95% CI 0.22–0.43). The area under the summary receiver operating characteristic curve was 0.83. When integrated into a combined prediction model, FST demonstrated enhanced prognostic accuracy for RRT compared with its use as a stand-alone test. These findings suggest that FST is a promising bedside tool for identifying patients with AKI who are a high risk of requiring RRT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.